xDot Medical wins FDA nod for pivotal vascular closure trial

xDot Medical got FDA approval to start a pivotal IDE study of its xDot Access Management System, a large-bore vascular closure device for femoral arterial and venous access. The 266-patient trial could help define the system’s safety and effectiveness in structural heart and electrophysiology procedures.

Why it matters: - Large-bore catheter procedures can leave femoral access sites hard to close. - Vascular closure failure and access-site complications remain major clinical challenges as structural heart and electrophysiology procedures grow. - Evidence from the pivotal study could help determine whether xDot Access Management System can provide reliable hemostasis for large-bore arterial and venous closure.

What happened: - xDot Medical said the U.S. Food and Drug Administration approved its Investigational Device Exemption application to begin a pivotal clinical trial of xDot Access Management System. - The study will evaluate closure of femoral arterial and femoral venous access sites. - The company said the approval came on July 6, 2026. - The trial will be prospective, multicenter, dual-cohort, single-arm and open-label.

The details: - The study will enroll patients undergoing catheter-based interventional procedures that require large-bore femoral arterial or femoral venous access. - The trial is designed to enroll 266 subjects, including roll-in subjects. - Follow-up will continue through 30 days after the procedure. - Dr. Rahul P. Sharma, director of structural interventions at Stanford Healthcare, and Dr. Devi G. Nair, chief of cardiac electrophysiology and research at St. Bernards Medical Center, will serve as national principal investigators. - Dr. Susheel Kodali, a structural heart interventional cardiologist who advised xDot Medical since early development and led the first-in-human study, said the device was engineered to address large-bore vascular closure challenges with maintained guidewire access and automated coaxial suture cinching. - xDot Medical said the xDot Access Management System is an investigational device and is not available for sale. - The company said it is currently enrolling patients in its Early Feasibility Study and plans to start enrollment in the pivotal study after the EFS is complete. - More information is available at xDot Medical.

Between the lines: - The FDA decision moves xDot Medical from early feasibility work into a larger, more formal test of safety and effectiveness. - Naming two national principal investigators from structural heart and electrophysiology signals the company is targeting multiple large-bore use cases. - The open-label, single-arm design means the study is focused on performance in practice rather than direct comparison with a control device.

What's next: - xDot Medical will finish enrollment in the Early Feasibility Study before beginning enrollment in the pivotal trial. - The company and investigators will track outcomes through the 30-day follow-up window. - The pivotal data set could shape the future clinical role of xDot Access Management System in large-bore vascular closure.